Genetics of Cisplatin Ototoxicity: Confirming the Unexplained?

被引：8

作者：

Boddy, A. V. ^{[1
]}

机构：

[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 94卷 / 02期

关键词：

ADJUVANT TAMOXIFEN; HEARING-LOSS; CHILDREN; CYP2D6; TPMT; VARIANTS; COMT;

D O I：

10.1038/clpt.2013.116

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Replication of findings in clinical pharmacogenetic studies is essential but often neglected. The observation that TPMT and COMT genotypes, in combination with ABCC3 genotype, are predictive of ototoxicity following cisplatin treatment has been confirmed. However, translating this observation into a useful preventive strategy requires more mechanistic insight.

引用

页码：198 / 200

页数：4

共 11 条

[1] Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
Barginear, M. F.
Jaremko, M.
Peter, I.
Yu, C.
Kasai, Y.
Kemeny, M.
Raptis, G.
Desnick, R. J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 605 - 611
[2] Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity
Harned, Theresa M.
Kalous, Ondrej
Neuwelt, Alexander
Loera, Jason
Ji, Lingyun
Lovine, Peter
Sposto, Richard
Neuwelt, Edward A.
Reynolds, C. Patrick
[J]. CLINICAL CANCER RESEARCH, 2008, 14 (02) : 533 - 540
[3] CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
Kelly, Catherine M.
Pritchard, Kathleen I.
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) : 427 - 428
[4] Muldoon LL, 2000, CLIN CANCER RES, V6, P309
[5] Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma
Picton, S. V.
Keeble, J.
Holden, V.
Errington, J.
Boddy, A. V.
Veal, G. J.
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (04) : 749 - 752
[6] Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
Pussegoda, K.
Ross, C. J.
Visscher, H.
Yazdanpanah, M.
Brooks, B.
Rassekh, S. R.
Zada, Y. F.
Dube, M-P
Carleton, B. C.
Hayden, M. R.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 243 - 251
[7] Carboplatin-Associated Ototoxicity in Children With Retinoblastoma
Qaddoumi, Ibrahim
Bass, Johnnie K.
Wu, Jianrong
Billups, Catherine A.
Wozniak, Amy W.
Merchant, Thomas E.
Haik, Barrett G.
Wilson, Matthew W.
Rodriguez-Galindo, Carlos
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1034 - 1041
[8] Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy (vol 41, pg 1345, 2009)
Ross, Colin J. D.
Katzov-Eckert, Hagit
Dube, Marie-Pierre
Brooks, Beth
Rassekh, S. Rod
Barhdadi, Amina
Feroz-Zada, Yassamin
Visscher, Henk
Brown, Andrew M. K.
Rieder, Michael J.
Rogers, Paul C.
Phillips, Michael S.
Carleton, Bruce C.
Hayden, Michael R.
[J]. NATURE GENETICS, 2013, 45 (05) : 578 - 578
[9] Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
Ross, Colin J. D.
Katzov-Eckert, Hagit
Dube, Marie-Pierre
Brooks, Beth
Rassekh, S. Rod
Barhdadi, Amina
Feroz-Zada, Yassamin
Visscher, Henk
Brown, Andrew M. K.
Rieder, Michael J.
Rogers, Paul C.
Phillips, Michael S.
Carleton, Bruce C.
Hayden, Michael R.
[J]. NATURE GENETICS, 2009, 41 (12) : 1345 - U118
[10] Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Schroth, Werner
Antoniadou, Lydia
Fritz, Peter
Schwab, Matthias
Muerdter, Thomas
Zanger, Ulrich M.
Simon, Wolfgang
Eichelbaum, Michel
Brauch, Hiltrud
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5187 - 5193

← 1 2 →